Research programme: antibody drug conjugate therapeutics - Medicovestor/Sanyou Biopharmaceuticals
Latest Information Update: 08 Oct 2025
At a glance
- Originator Medicovestor; Sanyou Biopharmaceuticals
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Cancer